Johnson & Johnson $JNJ Shares Bought by Uhlmann Price Securities LLC

Key Points

• Uhlmann Price Securities LLC increased its Johnson & Johnson stake by 149.7% in the first quarter, buying 8,301 additional shares and bringing its holding to 13,846 shares worth about $3.31 million.
• Johnson & Johnson has several positive business catalysts in the news, including encouraging prostate cancer drug Erleada data and plans to invest more than $1 billion in a Florida contact lens manufacturing facility.
• The company remains a favored income stock: it raised its quarterly dividend to $1.34 per share and has a consensus analyst rating of Moderate Buy with an average price target of $253.04.

Uhlmann Price Securities LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 149.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,846 shares of the company's stock after acquiring an additional 8,301 shares during the quarter. Johnson & Johnson comprises about 0.2% of Uhlmann Price Securities LLC's investment portfolio, making the stock its 17th biggest holding. Uhlmann Price Securities LLC's holdings in Johnson & Johnson were worth $3,309,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Sierra Capital LLC increased its position in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock valued at $1,685,000 after purchasing an additional 41 shares during the period. Beaird Harris Wealth Management LLC boosted its stake in Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock valued at $501,000 after buying an additional 42 shares in the last quarter. Broadleaf Partners LLC boosted its stake in Johnson & Johnson by 0.6% during the fourth quarter. Broadleaf Partners LLC now owns 7,348 shares of the company's stock valued at $1,521,000 after buying an additional 43 shares in the last quarter. Jessup Wealth Management Inc grew its holdings in Johnson & Johnson by 0.6% during the fourth quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company's stock worth $1,567,000 after acquiring an additional 44 shares during the period. Finally, Plancorp LLC raised its position in Johnson & Johnson by 0.3% in the fourth quarter. Plancorp LLC now owns 15,889 shares of the company's stock worth $3,288,000 after acquiring an additional 45 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s prostate cancer drug Erleada showed encouraging clinical results, with Reuters-reported data indicating it cut the risk of cancer spread or death by 20% in a study setting. That kind of pipeline progress can support longer-term revenue growth. Article Title
• Positive Sentiment: The company continues to be highlighted as a strong dividend stock, with articles pointing to Johnson & Johnson’s long history of dividend increases and its appeal to income-focused investors seeking stability in a volatile market. Article Title
• Positive Sentiment: Johnson & Johnson announced plans to invest more than $1 billion in a Florida contact lens manufacturing facility, reinforcing confidence in future operating capacity and U.S. production investment. Article Title
• Neutral Sentiment: Several commentary pieces describe JNJ as a defensive name that may hold up better if markets weaken, but these articles are largely opinion-based and do not add new fundamental catalysts. Article Title
• Negative Sentiment: Shares have been soft over the past few months, with one note saying the stock is down about 3% in three months despite solid results and pipeline progress. That recent weakness may be weighing on sentiment even as investors debate whether the dip is attractive. Article Title

Analysts Set New Price Targets

A number of equities research analysts have weighed in on JNJ shares. Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a "market perform" rating in a report on Wednesday, April 15th. Weiss Ratings downgraded shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b-)" rating in a report on Monday, June 15th. TD Cowen began coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They set a "buy" rating and a $250.00 target price for the company. Morgan Stanley set a $283.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Daiwa Securities Group upped their price target on Johnson & Johnson from $237.00 to $246.00 and gave the company an "outperform" rating in a report on Thursday, April 16th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Price Performance

NYSE JNJ opened at $228.37 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71. The company has a market cap of $549.73 billion, a PE ratio of 26.40, a PEG ratio of 2.24 and a beta of 0.26. The stock's 50-day moving average price is $230.61 and its two-hundred day moving average price is $228.25.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. During the same period last year, the company posted $2.77 earnings per share. The business's revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.3%. The ex-dividend date was Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio is presently 61.97%.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.